Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity

Ramona Dolscheid-Pommerich1 | Eva Bartok1 | Marcel Renn1,2,3 | Beate M. Kümmerer4 | Bianca Schulte4 | Ricarda M. Schmithausen5 | Birgit Stoffel-Wagner1 | Hendrik Streeck4 | Sandra Saschenbrecker6 | Katja Steinhagen6 | Gunther Hartmann1

1Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany
2Mildred Scheel School of Oncology, Bonn, Germany
3University Hospital Bonn, Medical Faculty, Bonn, Germany
4Institute of Virology, University Hospital Bonn, Bonn, Germany
5Institute for Hygiene and Public Health, University Hospital Bonn, Bonn, Germany
6Institute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany

Abstract
In the current COVID-19 pandemic, a better understanding of the relationship between merely binding and functionally neutralizing antibodies is necessary to characterize protective antiviral immunity following infection or vaccination. This study analyzes the level of correlation between the novel quantitative EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG) and a microneutralization assay. A panel of 123 plasma samples from a COVID-19 outbreak study population, preselected by semi-quantitative anti-SARS-CoV-2 IgG testing, was used to assess the relationship between the novel quantitative ELISA (IgG) and a microneutralization assay. Binding IgG targeting the S1 antigen was detected in 106 (86.2%) samples using the QuantiVac ELISA, while 89 (72.4%) samples showed neutralizing antibody activity. Spearman’s correlation analysis demonstrated a strong positive relationship between anti-S1 IgG levels and neutralizing antibody titers (r_s = 0.819, p < 0.0001). High and low anti-S1 IgG levels were associated with a positive predictive value of 72.0% for high-titer neutralizing antibodies and a negative predictive value of 90.8% for low-titer neutralizing antibodies, respectively. These results substantiate the implementation of the QuantiVac ELISA to assess protective immunity following infection or vaccination.

KEYWORDS
COVID-19, ELISA, microneutralization, SARS-CoV-2

1 | INTRODUCTION
In the current COVID-19 pandemic, the development of validated, standardized serological assays that quantitatively assess the antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of crucial importance. These assays serve multiple purposes, including the quantification of antibodies against SARS-CoV-2, the collection of data for epidemiological surveillance and control, postvaccination monitoring, or the screening of recovered COVID-19 patients for convalescent plasma therapy.1-3 The formation of SARS-CoV-2-specific antibodies that effectively reduce virulence/pathogenicity is likely to be crucial for the development of population immunity, which in turn is a major prerequisite to halt the COVID-19 pandemic.4-5 For the determination of neutralizing activity in
patient sera, neutralization assays based on live viral particles serve as the reference gold standard, assessing the presence of antibodies that inhibit infection of cultured cells (e.g., plaque-reduction neutralization test or microneutralization assay). These test systems, however, are time- and labor-intensive, restricted to biosafety level 3 laboratories, difficult to standardize, not automatable, and their implementation on a large scale is logistically impracticable. These limitations might be overcome by using standardized commercially available serological tests that are essentially based on recombinant SARS-CoV-2 antigens, focusing on the highly immunogenic spike (S) protein, including the S1 domain and receptor-binding domain (RBD), or the nucleocapsid protein. It is, however, still unknown what threshold titer of neutralizing antibodies confers protective immunity and whether results from commercial assays are capable of predicting such immunity. One prerequisite would be a strong correlation with neutralization activity, but pertinent data are limited and indicate that the accuracy in predicting levels of neutralizing antibodies can differ considerably between the assays.

The present study investigated the level of correlation between a novel standardized enzyme-linked immunosorbent assay (ELISA) for the quantitative detection of anti-SARS-CoV-2 S1 IgG and a microneutralization assay.

2 METHODS

2.1 Plasma samples

Plasma samples originated from a cross-sectional seroepidemiological study conducted between March 31, 2020, and April 6, 2020, in the community of Gangelt (Heinsberg district, North Rhine-Westphalia, Germany), where a carnival celebration on February 15, 2020, led to SARS-CoV-2 super-spreading. The original dataset was filtered for participants that had been categorized as seropositive based on IgG reactivity in the semiquantitative anti-SARS-CoV-2 ELISA IgG (EUROIMMUN Medizinische Labordiagnostika AG). A total of 123 plasma samples were available for further testing in the present study, including 106 anti-S1 IgG positive (ratio ≥ 1.1) and 17 borderline (ratio 0.8–1.1) samples according to semiquantitative pre-verification. These samples were from individuals (45.5% male, mean age 49.6 years, range 3–87 years), of whom 29 (23.6%) were asymptomatic and 94 (76.4%) oligosymptomatic. For more details about the demographics of the study cohort, see Streeck et al. EDTA plasma was stored at −80°C until analysis.

The study was approved by the Ethics Committee of the Medical Faculty of the University of Bonn (approval number 085/20) and has been registered at the German Clinical Trials Register (https://www.drks.de, identification number DRKS00021306, study arm 1).

2.2 Enzyme-linked immunosorbent assay

The EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG), hereafter referred to as QuantiVac ELISA, was processed on the EUROIMMUN Analyzer I platform according to the manufacturer's instructions. The ELISA is based on 96-well microcoated with the SARS-CoV-2 S1 domain (including RBD) expressed recombinantly in the human cell line HEK293 (ATCC). The data sheet reports no cross-reactivities with samples from patients infected with SARS-CoV-1, HCoV-229E, or HCoV-OC43. Quantification of S1-specific IgG was performed using a 6-point calibration curve covering a range from 1 to 120 relative units (RU)/ml. Samples yielding results above this analytical range were re-evaluated at a higher dilution. Positive and negative controls were included in each test run. By multiplication with factor 3.2, results in RU/ml were converted into standardized binding antibody units (BAU)/ml. Results <25.6 were considered negative, ≥25.6 to <35.2 borderline, and ≥35.2 positive.

2.3 Virus microneutralization assay (CPE reduction NT assay)

Microneutralization assays were performed as previously described using a SARS-CoV-2 strain (SARS-CoV-2/human/Germany/Heinsberg-01/2020, lineage B.3) that had been isolated from a throat swab of an infected patient at the University of Bonn, Germany in March 2020. In brief, plasma samples were heat-inactivated at 56°C for 30 min. Twofold serial plasma dilutions (starting from 1:2) were prepared in triplicate on a 96-well plate in Dulbecco’s modified Eagle medium (+3% fetal bovine serum; Gibco). The dilutions were incubated with an equal volume of 100 TCID50 SARS-CoV-2 solutions for 1 h at 37°C. A suspension containing 2 × 10⁴ Vero E6 cells was added to each well and plates were incubated at 37°C (5% CO₂) for 2 days. The cytopathic effect (CPE) was evaluated via microscopy. Neutralizing antibody titers were calculated using the Spearman–Kærber formula and indicate the reciprocals of the highest plasma dilution protecting 50% of the wells. A neutralization titer of 2.8 corresponded to CPE suppression in all three replicates of the 1:2 dilution. Samples with a neutralization titer ≥2.8 were considered positive. Samples showing CPE suppression in one or two wells of the 1:2 dilution were assigned a neutralization titer of 1.7 or 2.2, respectively, indicating borderline results. Samples showing a CPE equal or similar to the negative control (titer < 1.7) were considered negative.

2.4 Statistics

Confidence intervals (95% CI) were calculated according to the modified Wald method. Interassay concordance was assessed using the percentage of agreement and Kappa statistics, considering borderline results as positive. Cohen’s kappa coefficient was calculated using the formula Kappa(κ) = (P₀ – Pₑ)/(1 – Pₑ), where P₀ is the relative observed agreement, and Pₑ is the hypothetical probability of random agreement. Kappa values of 0–0.20, 0.21–0.40, 0.41–0.60, 0.61–0.80, and 0.81–1.00 indicate poor, fair, moderate, good, and very good agreement, respectively. Spearman rank-order correlation analysis was performed to evaluate the relationship between two assays. The unpaired
TABLE 1  Agreement between quantitative ELISA and microneutralization assay in 123 plasma samples obtained from inhabitants of a German community after a local SARS-CoV-2 super-spreading event

| CPE reduction NT assay | Agreement of assays* |
|------------------------|----------------------|
|                       | Positive n (%)       | Borderline n (%) | Negative n (%) | Positive agreement (95% CI) | 100% (95.0%–100%) |
| Anti-SARS-CoV-2         |                      |                   |                |                         |                   |
| QuantiVac ELISA (IgG)  | Positive             | 68 (72.4%)        | 18 (14.6%)     | 10 (8.1%)                | Negative agreement (95% CI) 50.0% (34.1%–65.9%) |
|                        | Borderline           | 0 (0%)            | 3 (2.4%)       | 7 (5.7%)                 | Overall agreement (95% CI) 86.2% (78.9%–91.3%) |
|                        | Negative             | 0 (0%)            | 0 (0%)         | 17 (13.8%)               | Kappa value (95% CI) 0.591% (0.427%–0.756%) |

*Borderline results were considered positive.

In 123 plasma samples that had been precharacterized as SARS-CoV-2 seropositive by semiquantitative IgG testing, anti-SARS-CoV-2 S1 IgG levels were measured quantitatively using the QuantiVac ELISA. Titers of neutralizing antibodies were determined by CPE reduction NT assay, ranging between <1.7 and 286 with a mean ± SD of 11.4 ± 33.6 (median, 3.5; IQR, 0–9.0).

Using the QuantiVac ELISA, 96 out of 123 samples were classified as positive, 10 as borderline, and 17 as negative. The CPE reduction NT assay yielded positive, borderline, and negative results in 68, 21, and 34 out of 123 cases, respectively (Table 1). Thus, if borderline results were considered positive, the sensitivity of the QuantiVac ELISA amounted to 86.2% (106/123) and that of the CPE reduction NT assay to 72.4% (89/123).

All 89 samples testing positive or borderline by CPE reduction NT assay were also anti-S1 IgG positive or borderline by QuantiVac ELISA, corresponding to a positive agreement rate of 100% (89/89). Among 34 neutralization-negative samples, 17 were negative for anti-S1 IgG by QuantiVac ELISA, resulting in a negative agreement rate of 50%. Accordingly, the overall agreement between the two assays amounted to 86.2% based on the correlation of positive and negative results in 106/123 cases. To correct the agreement for the probability of random coincidence, the Kappa coefficient was calculated (κ = 0.591) and indicated moderate agreement (Table 1).

Spearman rank-order correlation analysis revealed a strong positive, statistically significant association between the quantitative levels of anti-SARS-CoV-2 S1 IgG and the titers of neutralizing antibodies (rₛ = 0.819, p < 0.0001; Figure 1).

Comparison of the two groups revealed a significant difference between the mean neutralization titers (34.4 vs. 5.5, p < 0.0001). Median titers were 18.0 (IQR, 9.0–22.0) and 2.2 (IQR, 0–4.5) in the high and low groups, respectively. The positive predictive value (PPV) of high anti-S1 IgG for the presence of high-titer (≥10) neutralizing antibodies was 72.0% (52.2%–85.9%), whereas low anti-S1 IgG levels were associated with a negative predictive value (NPV) of 90.8% (83.3%–95.3%) for low-titer (<10) neutralizing antibodies.

FIGURE 1  Correlation between quantitative ELISA and microneutralization assay. Binding anti-SARS-CoV-2 S1 IgG was determined quantitatively using the QuantiVac ELISA and titers of neutralizing antibodies were determined using the CPE reduction NT assay (n = 123). Neutralization titers correspond to reciprocal plasma dilutions protecting 50% of the wells at incubation with 100 TCID₅₀ of SARS-CoV-2. Samples with a cytopathic effect (CPE) equal or similar to the negative control are depicted on the y-axis. Dotted and dashed lines indicate borderline and positivity cut-offs, respectively. rₛ, Spearman rank-order correlation coefficient

Conventional neutralization assays are unsuitable for large-scale routine testing in the current COVID-19 pandemic. This has raised the question as to whether there are standardized and scalable serological assays that show a degree of correlation allowing estimates on neutralizing activity to assess immunity to reinfection and to support vaccination programs or antibody-based therapeutic trials.
The primary semiquantitative EUROIMMUN Anti-SARS-CoV-2 ELISA IgG was also analyzed by other groups, indicating a high correlation with neutralization activity ($r_c = 0.75-0.88$). In this semiquantitative ELISA, the same S1 antigen is coated on the microplate wells as in the QuantiVac ELISA, giving a possible explanation for the similarly high degree of correlation observed in the present study.

The strong correlation of the QuantiVac ELISA with neutralization testing suggests a high potential to quantitatively predict neutralizing antibody titers. However, the QuantiVac ELISA results are not a 100% correlate of the CPE reduction NT assay, and it has to be considered that a part of neutralization potency seems to be mediated by S-specific IgM antibodies.$^{19-21}$ Therefore, the implementation of the QuantiVac ELISA should be evaluated for the different contexts of use where thresholds in anti-S1 IgG levels are accepted to predict neutralizing activity. In addition, it adds great value as a pre-screening tool for neutralization assessment, as it would strongly reduce the number of samples needing to undergo labor-intensive cell-based neutralization assays.

According to validation data on the clinical performance, the diagnostic sensitivity of the QuantiVac ELISA ranges between 90.3% (10 days post symptom onset [dpso], $n = 165$) and 93.2% (>20 dpso, $n = 46$), at a specificity of 99.8% based on measurements in 1458 samples from healthy and disease controls.$^{14}$

The QuantiVac ELISA is one of the first SARS-CoV-2 serological assays that allow reporting of quantitative results in standardized, WHO-approved binding antibody units (BAU/ml) which numerically correspond to international units (IU/ml). Optionally, the QuantiVac ELISA can be processed on fully automated equipment, enabling high throughput in the diagnostic workup.

This study has limitations, however. First, the study panel was limited in the number of samples, necessitating the confirmation of results in further studies. Second, as the assays were not performed simultaneously, differences in storage time and freeze-thaw cycles may have affected the measurement of antibody levels.

In summary, the QuantiVac ELISA provides quantitative levels of anti-S1 IgG, allowing confirmation and monitoring of recent and past SARS-CoV-2 infections. Strong correlation with neutralization testing substantiates its implementation in clinical diagnostics and vaccination monitoring.

ACKNOWLEDGMENTS

Postpublication open access was funded by EUROIMMUN Medizinische Labordiagnostika AG. The authors would like to thank the following people for excellent technical assistance and other types of support: N. Langer, D. Wilken, O. Klemens, J.M. Klemens, and J. Wieseler. Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTERESTS

Sandra Saschenbrecker and Katja Steinhagen are employed by EUROIMMUN Medizinische Labordiagnostika AG, a manufacturer of diagnostic reagents and co-owner of a patent application pertaining to the detection of antibodies to the SARS-CoV-2 S1 antigen. Katja Steinhagen is designated as an inventor. The other authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Gunther Hartmann and Katja Steinhagen contributed to the conception and design of the study. Hendrik Streeck, Ramona Dolscheid-Pommerich, Marcel Renn, Beate M. Kümmerer, Bianca Schulte, Eva Bartok, Gunther Hartmann, and Katja Steinhagen were involved in sample collection and performed acquisition and analysis of data. The manuscript was written by S. Saschenbrecker, Gunther Hartmann, and Katja Steinhagen. All authors had access to the data, revised the manuscript, and approved the final version.

DATA AVAILABILITY STATEMENT

Data are available on request from the authors.

ORCID

Ramona Dolscheid-Pommerich https://orcid.org/0000-0002-1266-8003
Ev Bartok https://orcid.org/0000-0003-0556-1950
Marcel Renn https://orcid.org/0000-0002-0120-4035
Beate M. Kümmerer https://orcid.org/0000-0002-9011-2764
Bianca Schulte https://orcid.org/0000-0003-1096-3751
Ricarda M. Schmithansen https://orcid.org/0000-0002-3736-8672
Hendrik Streeck https://orcid.org/0000-0002-0335-6390
Sandra Saschenbrecker https://orcid.org/0000-0002-4769-915X
Gunther Hartmann https://orcid.org/0000-0003-1021-2018
REFERENCES

1. Krammer F, Simon F. Serology assays to manage COVID-19. Science. 2020;368:1060-1061.
2. Lee CY, Lin RTP, Renia L, Ng LFP. Serological approaches for COVID-19: Epidemiologic perspective on surveillance and control. Front Immunol. 2020;11:879.
3. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol. 2020;58:58.
4. Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443-449.
5. Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956-963.
6. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11:610688.
7. Nguyen NNT, McCarthy C, Lantigua D, Camci-Unal G. Development of diagnostic tests for detection of SARS-CoV-2. Diagnostics. 2020; 10:905.
8. Luchsinger LL, Ransegnola BP, Jin DK, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol. 2020;58:58.
9. Schlickeiser S, Schwarz T, Steiner S, et al. Disease severity, fever, age, and sex correlate with SARS-CoV-2-neutralizing antibody responses. Front Immunol. 2020;11:628971.
10. Walker GJ, Naing Z, Ospina SA, et al. SARS coronavirus-2 micro-neutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays. Viruses. 2021:13.
11. Weidner L, Gansdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol. 2020;129:104540.
12. Jahrsdörfer B, Kroschel J, Ludwig C, et al. Independent side-by-side validation and comparison of 4 serological platforms for SARS-CoV-2 antibody testing. J Infect Dis. 2021;223:796-801.
13. Streeck H, Schulte B, Kümmerer BM, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat Commun. 2020;11:5829.
14. EUROMMUN. Anti-SARS-CoV-2 QuantiVac ELISA (IgG), Package Insert, EI_2606-10G_A_UK_CO2.docX Version: 2021-02-03. 2021.
15. Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5:85-86.
16. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
17. Rubio-Acero R, Castelletti N, Fingerle V, et al. In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther. 2021;10:1505-1518.
18. Harvala H, Robb ML, Watkins N, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2020;31:167-175.
19. Prévost J, Gasser R, Beaudoin-Bussières G, et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep Med. 2020;1:100126.
20. Gasser R, Cloutier M, Prévost J, et al. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep. 2021;34:108790.
21. Klingler J, Weiss S, Itri V, et al. Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome coronavirus 2. J Infect Dis. 2021;223:957-970. https://academic.oup.com/jid/article/223/6/957/6047279?searchresult=1

How to cite this article: Dolscheid-Pommerich R, Bartok E, Renn M, et al. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J Med Virol. 2022;94:388-392. https://doi.org/10.1002/jmv.27287